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Antimicrobial resistance is a major
health issue and a worldwide problem. The
O’Neill report published in 2016 analyses
different aspects and provides an extrapola-
tion of the consequences.1 An increasing
number of stakeholders are recognizing the
fact that such a large and complex problem
requires multiple approaches tackling it
from different angles and perspectives – the
One Health approach.2 It is not just a prob-
lem in hospitals for medical professionals to
solve. Antibiotic resistance is much more
complex. It is also about over-use of antibi-
otics in livestock, about general over use in
general practice, about unregulated access,
about long-term care facilities, about fre-
quent and easy travelling across the globe,
about the pharmaceutical industry and
financial incentives, both in general econo-
my as well as in health care insurance. So
many factors have a wide economic impact
across all different sectors.3 This has drawn
political attention and action so as to stimu-
late all parties to work together towards a
sustainable future from a One Health per-
spective. 
Patients’ safety against healthcare asso-
ciated infections (HAI) is a key indicator of
the quality of healthcare. This has been
underlined recently by the first report on
communicable diseases of the European
Centres for Disease Prevention and Control
stating that HAI without or with antimicro-
bial resistance [e.g. Methicillin-resistant
Staphylococcus aureus [MRSA], and car-
bapenem-resistant Enterobacteriaceae
(CRE)] are the most important infectious
disease threat in the European Union, rank-
ing higher than HIV, pneumococcal infec-
tions and influenza.4 This is furthermore
underlined by the recent publication of the
WHO list of Top-12 organisms wherein the
most critical microorganisms all are most
frequent causes of healthcare-associated
and less frequently community-associated
infections [e.g. carbapenem-resistant
Acinetobacter baumanii (CRAB)]. Within a
given healthcare system, the spread of
antimicrobial resistant microorganisms
(AMR) is largely determined by the flux of
patients through referral networks.5 With
those patients AMR are transferred, as well.
It is thus crucial to take these referral net-
works into account when organizing meas-
ures for Antimicrobial Stewardship and pre-
vention of AMR. This concept has led to the
most recent Dutch approach of creating ten
regional health care regions.6 This concept
has been also adopted on a supranational
level, e.g. in the EU. The importance of
antimicrobial resistance as a factor which
increases mortality and morbidity of com-
municable disease for patients in European
member states has been expressed by the
Council Resolution (1999/C195/01) on
antimicrobial resistance claiming a strategy
against the threat of antimicrobial resist-
ance. Different healthcare systems, such as
the Dutch and the German are strongly
divided by two totally different prevalences
of healthcare-associated infections (HAI).
This is difference is especially caused by
AMR, such as MRSA, Vancomycin-resis-
tant Enterococcus faecium or carbapenem-
resistant Pseudomonas aeruginonsa. The
EUREGIO networks MRSA-net and
EurSafety Health-net (www.eursafety.eu)
have shown that infections with MRSA
occur up to 32 times more frequently in
Germany than in the Netherlands.7 On the
other side it made clear that in the
Netherlands there are up to 3 times fewer
hospital-beds per 1000 inhabitants and up to
4 times fewer doctors in outpatient service,
making access to health care and possibly to
most antibiotics also difficult. Higher rates
of death due to pneumonia in the
Netherlands might be an indicator for lower
accessibility to healthcare services, leading
to a late diagnosis. A proper (tentative)
diagnosis in turn is needed for a prudent use
of antibiotic treatment, as has been also
underlined by the Council recommendation
(2002/77/EC).
Whilst we recognise that the link
between use in livestock and agriculture on
the one side and resistance in humans is still
not completely understood, antimicrobial
use in the livestock and agricultural sectors
is several times more than is used for
humans.8 Estimates range from roughly
63,000 tons globally in 2010, rising to
roughly 105,000 tons in 20309 to several
hundred thousand tons.10
This issue of Infectious Disease Reports
addresses the challenge of antimicrobial
resistance from different perspectives and
provides examples of different solutions
that people are actively pursuing with a
focus on the health care sector and sustain-
able use of antimicrobials. This issue focus-
es on the clinical (inpatient) setting where
the impact of resistant infections is current
greatest leading to use of last resort antimi-
crobials. It is this setting that also most
urgently identifies the need for a balanced
approach to antimicrobial resistance- sup-
porting innovation through developing new
antibiotics and preservation of existing
antimicrobials- antimicrobial stewardship.
Antimicrobial stewardship programmes
(ASP) immersed in a model that integrates
appropriate and timely diagnostics and an
optimal infection prevention and control
programme perhaps is an effective model
for optimising the clinical response to drug
resistant infection in this setting.11 Adaption
of such a model is clearly important and
dependent on local resources, geography,
cultures and healthcare systems. 
ASPs usually comprise bundles of inter-
ventions designed to increase prudent use of
antimicrobials by a range of restrictive and
persuasive methods including guidelines,
pre-authorisation, review, audit and feed-
back, supported by education and incen-
tives.12 Core stewardship interventions are
local guidelines and education. The impor-
tance of educating the multi-professional
healthcare team in delivering antibiotics
effectively and safely is critical. Rocha-
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Pereira et al. provide an overview of a range
of traditional and novel educational meth-
ods currently employed to support steward-
ship.13 In order to provide the correct and
treatment, identifying the organism through
better use of existing and novel diagnostics
is vital. Indeed, establishing a correct diag-
nosis is one quality indicator for optimal
treatment. Maurer et al. show an overview
of new techniques that are being developed
right now and discuss the impact of those
diagnostic modalities on ASPs.14
Furthermore, the systematic review of
Kallen and Prins looked at quality indica-
tors described in the literature and provide
an overview.15 Such indicators are impor-
tant when establishing an ASP and as a
means of evaluating its impact over time. If
all is in place and an institution is able to
provide optimal antimicrobial therapy, the
effects will differ for each patient. One
striking example of the impact of this treat-
ment is in the case of bloodstream infec-
tions (BSIs). Without proper and timely
action, a BSI can be fatal for the patient.
Therefore, there has been a strong focus on
providing the correct treatment with antimi-
crobials for patients with BSIs. Coulter et
al. provide an overview of the literature
published on this topic.16 Besides the rather
evident clinical impact of optimal antimi-
crobial use, there is also a strong economic
impact. It is important to consider this when
implementing an ASP in an institution. As
this special issue of IDR shows, a
Stewardship for infections consists of many
aspects and many different people involved
during the whole process of infection man-
agement. Technical support is thus an
important aspect. A wide range of eHealth
tools exists to support healthcare profes-
sionals in their tasks. Beerlage-De Jong et
al. review these tools and their impact dur-
ing the implementation of an ASP.17 A sys-
temic perspective is highly important for a
useful financial evaluation of any interven-
tion. Dik et al. show aspects of a sustainable
financial implementation of an ASP.18 Over
the years, there are numerous publications
of studies regarding the financial impact of
ASPs. Oberjé et al. provide some best prac-
tices from different European studies,
showing that there are already interesting
publications that describe a positive finan-
cial impact.19 Finally, coming back to the
One Health approach, the economic impact
can be seen at an even bigger scale, includ-
ing also e.g. the costs of the development of
new antimicrobials. This is an issue that still
is not solved completely. Theuretzbacher et
al. provide more insight into this important
topic.20 Showing that this problem is too big
to approach from just the hospital or clinical
perspective. 
To optimally address the global chal-
lenge of increasing antimicrobial resistance
major, coordinated efforts are required.
They need to involve all stakeholders, i.e.
patients, healthcare providers (both for
inpatients and outpatients), scientists,
healthcare insurances, pharmaceutical
industry, agriculture/livestock, sewage and
garbage facilities, regulatory institutions,
and politics. All stakeholders need to col-
laborate in order to halt antimicrobial resis-
tance development and spread. This issue
aims at providing insights and viewpoints
regarding this goal. 
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